You may notice DexCom, Inc. (DXCM) - Get Free Report on your list of biggest losers for the stock market on Thursday. Shares are being hammered, down about 36% to new 52-week lows on the entrance of Abbott Labs (ABT) - Get Free Report into one of its key markets.
In fact, DexCom stock is hitting its lowest levels since late-2014 on the news. "This is a real shot" by Abbott, TheStreet's Jim Cramer said on CNBC's "Stop Trading" segment.
So what's happening? The FDA has approved Abbott's FreeStyle Libre Flash Glucose Monitoring System. In fact, it's the first blood glucose monitoring system that doesn't require patients to prick their finger. The device is worn on the back of patients' upper arm and can continuously monitor glucose levels for 10 days.
There's good characteristics to the new device, and investors are realizing just how competitive it can be against DexCom's offering, Cramer reasoned. The differing sizes of the companies doesn't help. Abbott's $94 billion market cap dwarfs the now sub-$4 billion market cap of DexCom.
- Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway
- Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked
- Apple, Fitbit Part of FDA Pilot Program to Expedite Health Devices to Market
In other words, Abbott has far more flexibility, resources and marketing power behind the new device, which could really put the pressure on DexCom. MediCare and the FDA are really going to like the new device, said Cramer, who also manages the Action Alerts PLUS charitable trust portfolio.
"I think that Abbott is a buy, even up here," Cramer concluded. Ironically, Abbott Labs is up 3.6% and hitting new 52-week highs in Thursday's session, now up 41% on the year.
More of What's Trending on TheStreet:
- Dunkin' CEO Reveals Secret Weapon to Win Coffee War With McDonald's: Real Coffee
- My Apple Watch Series 3 Sent the Police to My Apartment: An Unapologetic Review
- They Think it's All Over? Bain-Apple Pays $18 Billion for Toshiba Chip Unit
- Trump Tax Plan Cuts Corporate Rate, Raises Lowest Rate, Leaves Lots Out
At the time of publication, Jim Cramer's Action Alerts PLUS had a position in ABT.